KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Deferred Taxes (2018 - 2025)

Historic Deferred Taxes for Xenon Pharmaceuticals (XENE) over the last 8 years, with Q3 2025 value amounting to -$701000.0.

  • Xenon Pharmaceuticals' Deferred Taxes fell 11770.19% to -$701000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 226637.17%. This contributed to the annual value of -$8.9 million for FY2024, which is 293561.64% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Deferred Taxes of -$701000.0 as of Q3 2025, which was down 11770.19% from -$170000.0 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Deferred Taxes high stood at $403000.0 for Q1 2024, and its period low was -$8.6 million during Q4 2024.
  • Moreover, its 5-year median value for Deferred Taxes was -$170000.0 (2025), whereas its average is -$590842.1.
  • Its Deferred Taxes has fluctuated over the past 5 years, first soared by 276666.67% in 2022, then plummeted by 420600.0% in 2024.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Deferred Taxes stood at $346000.0 in 2021, then tumbled by 98.55% to $5000.0 in 2022, then tumbled by 4100.0% to -$200000.0 in 2023, then plummeted by 4206.0% to -$8.6 million in 2024, then skyrocketed by 91.86% to -$701000.0 in 2025.
  • Its Deferred Taxes stands at -$701000.0 for Q3 2025, versus -$170000.0 for Q2 2025 and -$1.2 million for Q1 2025.